Feed / CELC

Celcuity Inc. Common Stock

CELC

Healthcare · 93.66 +3.4% today

Partial group confirmationMarket checked 21 Aug, 15:55 GMT-4

Jodie situation report

Celcuity Inc. Common Stock's move is being confirmed by its market group.

CELC accounts for 33.3% of the group's measured movement across 3.9 effective names. raw member direction is mixed; 3 of 5 session-normalized paths align to the downside. Capital-flow agreement is 29%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

Session-normalized 5m paths
Role in the moveDominant mover#1 of 5 by movement share
Group movement share33.3%Absolute path energy—not portfolio weight
Relative path+2.88%counter
Effective breadth3.9 / 5balanced
Relative alignment3/5downside path · 2 counter-moving
Capital-flow agreement29%not yet clean
SEQUENCE READ

IDYA moved materially before CELC. CELC crossed its material path threshold at 10:15 ET, 45 minutes after the first measured mover. RVMD, BCRX, ABVX followed.

EVIDENCE COVERAGE

5 of 5 members in Clinical Biotechnology are active. 0 of 2 disclosed connections are confirming.

What would change this read
  • At least 4 of 5 members remain active in the next snapshot.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as ABCL begins moving with the group.

Invalidation: The live read weakens if participation falls to 1 of 5 members or fewer.

Watch this read

Who this business touches

The relationships behind CELC

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

JEFJefferies Financial Group Inc.partnerNov 13, 2025 ▾

“Open Market Sale Agreement On February 4, 2022, we entered into an Open Market Sale Agreement with Jefferies LLC (“Jefferies”), as agent, pursuant to which we may offer and sell, from time to time, through Jefferies, shares of our common stock having an aggre…”

PFEPfizer, Inc.partnerMay 14, 2026 ▾

“In April 2021, we obtained exclusive global development and commercialization rights to gedatolisib under a license agreement with Pfizer.”

Filing peers

IMRX

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

CELC is currently a Follower in the organic co-movement group Clinical Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.